Although the changes in tumour immune cell infiltration and phenotype are likely to be a consequence of reduce lactate in the tumour microenvironment following MCT1 blockade,15 we wanted to assess the impact of AZD3965 treatment on MCT1 activity in immune cells themselves. This evidence concerns the gene SLC16A1 and neoplasm.